IBCG
@ibcg_bladderca
We (the IBCG, International Bladder Cancer Group) are a group who are devoted to positively affecting the care of bladder cancer patients globally.
ID: 4859007953
http://ibcg.info 29-01-2016 04:40:35
1,1K Tweet
1,1K Followers
393 Following
Managing variant histology in high-risk non-muscle invasive #BladderCancer. Cookson, Michael University of Oklahoma Urology & Paolo Gontero MolinetteUrology discuss with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center as part of the IBCG #BladderCancerForum > bit.ly/3xyeyRr
To TURBT or Not to TURBT? Evaluating treatment options for recurrent low-grade, intermediate-risk bladder tumors. Sarah P. Psutka MD MS University of Washington & Prof Param Mariappan 🇬🇧 🇲🇾 Edinburgh Bladder Cancer Surgery (EBCS) join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center as part of this IBCG #BladderCancerForum > bit.ly/4eTLjJu
⚡️ Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection #BladderCancer OncoAlert Shilpa Gupta Hikmat Al Ahmadie Ashish M. Kamat, MD, MBBS
Guidance for #BladderSparing treatment IBCG #BladderCancer ✅Several treatment options available to explore bladder sparing approach safely ✅Thorough clinical response assessment needed (consider PDD) ✅ TMT/RC in case of failure Ashish M. Kamat, MD, MBBS OncoDaily Shilpa Gupta
#WatchNow Rashid K. Sayyid University of Toronto and Zach Klaassen Georgia Cancer Center discuss the Society for Immunotherapy of Cancer and the IBCG recommendations for clinical trials in #BladderCancer in this conversation on UroToday > bit.ly/4c3WwFE
Exploring the complexities of #BladderCancer surveillance: cytology, UroVysion, and beyond. Komal Pohar & Kelly Bree discuss urinary markers with Ashish M. Kamat, MD, MBBS as part of this Amer. Urol. Assn. IBCG #BladderCancerForum > bit.ly/4dZmgEv
Andrea Necchi is a true visionary and a trailblazer in GU cancers! What a fantastic talk!! #ESMO24 Philippe spiess Global Society of Rare GU Tumors IBCG
Phenomenal talk by brilliant Andrea Necchi who co-founded Global Society of Rare GU Tumors with the amazing Philippe spiess trying to meet a very important global need & address disparities! Shilpa Gupta Andrea Apolo, M.D. ESMO - Eur. Oncology #ESMO24 #ESMOAmbassadors OncoAlert IBCG Ashish M. Kamat, MD, MBBS Roger Li
Thrilled to be working alongside such a phenomenal team! Excited for our collaboration to tackle rare variants in #BladderCancer Philippe spiess Andrea Necchi Petros Grivas Sumanta K. Pal, MD, FASCO Shilpa Gupta Roger Li Jonathan Rosenberg MD Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition Andrea Apolo, M.D.
Timing and rationale for repeat TURBT: Perspectives on improving #BladderCancer outcomes. Badrinath Konety, MD, MBA Allina Health & Jeremy Teoh CUHK Medicine join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in this discussion on UroToday > bit.ly/4bjvj1h IBCG #BladderCancerForum
Thank you to #ESMO2024 committee for the opportunity to discuss these interesting trials #HiroshiKitamura Lars Dyrskjøt Andrea Necchi! Very excited for the shifting landscape of bladder cancer! Stephanie Chisolm, PhD IBCG Huntsman Cancer Institute
Excited to see this work by the exceptional team Valar Labs presented at #IBCN24 IBCN in Bern 🇨🇭 👉large international cohort validating a novel AI powered bladder cancer histologic biomarker predicts outcomes.🔥👍💫 Bladder Cancer Advocacy Network UroToday.com IBCG UTMBUrology
This collaboration holds immense promise. By leveraging collective strengths, we can make a significant positive impact on the quality of care for #bladdercancer Stephen B. Williams, MD, MBA, MS, FACHE Ashish M. Kamat, MD, MBBS Roger Li Kent Mouw Andrea Necchi Peter Black Shilpa Gupta Lars Dyrskjøt
Andrea Necchi presenting at #IBCN24 IBCN regarding the value of MRI in bladder cancer. Leverage tech improve diagnosis and management of BC. Also mindful global costs and use AI to add value. IBCG World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network UroToday.com UTMBUrology
Andrea Necchi presenting #IBCN24 IBCN SunRise 4 Neoadjuvant TAR 200 + cetrelimab v cetrelimab alone MIBC interim analysis showing significantly improve pCR and pOR rates for TAR 200 combo! Marked patients T2 & complete TURBT. IBCG Bladder Cancer Advocacy Network UroToday.com